A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841
This study is recruiting at 7 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- August 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford Cancer Center · Palo Alto, CA
Florida · 1
- Florida Cancer Specialists Sarasota Drug Development Unit · Sarasota, FL
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
North Carolina · 1
- Duke Cancer Institute · Durham, NC
Texas · 1
- NEXT Oncology · San Antonio, TX
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.